keyword
MENU ▼
Read by QxMD icon Read
search

Lymphoma stem cell

keyword
https://www.readbyqxmd.com/read/29339775/anti-apoptotic-a1-is-not-essential-for-lymphoma-development-in-e%C3%A2%C2%B5-myc-mice-but-helps-sustain-transplanted-e%C3%A2%C2%B5-myc-tumour-cells
#1
Mark Mensink, Natasha S Anstee, Mikara Robati, Robyn L Schenk, Marco J Herold, Suzanne Cory, Cassandra J Vandenberg
The transcription factor c-MYC regulates a multiplicity of genes involved in cellular growth, proliferation, metabolism and DNA damage response and its overexpression is a hallmark of many tumours. Since MYC promotes apoptosis under conditions of stress, such as limited availability of nutrients or cytokines, MYC-driven cells are very much dependent on signals that inhibit cell death. Stress signals trigger apoptosis via the pathway regulated by opposing fractions of the BCL-2 protein family and previous genetic studies have shown that the development of B lymphoid tumours in Eµ-Myc mice is critically dependent on expression of pro-survival BCL-2 relatives MCL-1, BCL-W and, to a lesser extent, BCL-XL, but not BCL-2 itself, and that sustained growth of these lymphomas is dependent on MCL-1...
January 16, 2018: Cell Death and Differentiation
https://www.readbyqxmd.com/read/29339268/incidence-of-second-primary-malignancies-after-autologous-transplantion-for-multiple-myeloma-in-the-era-of-novel-agents
#2
Firoozeh Sahebi, Simona Iacobelli, Giulia Sbianchi, Linda Koster, Didier Blaise, Péter Reményi, Nigel H Russell, Per Ljungman, Guido Kobbe, Jane Apperley, Marek Trneny, Marta Krejci, Wieslaw Wiktor-Jedrzejczak, James F Sanchez, Nicolaas Schaap, Cecilia Isaksson, Stig Lenhoff, Paul Browne, Christof Scheid, Keith M O Wilson, Ibrahim Yakoub-Agha, Soledad González Muñiz, Stefan Schönland, Curly Morris, Laurent Garderet, Nicolaus Kröger
The advent of novel agents for multiple myeloma (MM) is cause for a re-examination of the incidence of second primary malignancies (SPM). We examined the SPM rate in MM patients who were enrolled in the prospective observational Collaboration to Collect Autologous Transplant outcome in Lymphoma and Myeloma (CALM) study. Between 2008 and 2012, 3204 patients with MM underwent a first autologous hematopoietic stem cell transplantation (auto-HSCT). Plerixafor was used as a mobilizing agent for patients with poor (or potentially poor) stem cell mobilization as defined by the respective centers...
January 12, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29338540/efficacy-and-safety-of-frontline-rituximab-cyclophosphamide-doxorubicin-and-prednisone-plus-bortezomib-vr-cap-or-vincristine-r-chop-in-a-subset-of-newly-diagnosed-mantle-cell-lymphoma-patients-medically-eligible-for-transplantation-in-the-randomized-phase-3
#3
Johannes Drach, Huiqiang Huang, Olga Samoilova, Andrew Belch, Charles Farber, André Bosly, Jan Novak, Jan Zaucha, Angela Dascalescu, Udomsak Bunworasate, Zvenyslava Masliak, Kateryna Vilchevskaya, Tadeusz Robak, Lixia Pei, Brendan Rooney, Helgi van de Velde, Franco Cavalli
This post-hoc subanalysis of the LYM-3002 phase 3 study assessed the efficacy and safety of substituting vincristine in rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHOP; n = 42) for bortezomib (VR-CAP; n = 38) in a subgroup of 80 mantle cell lymphoma (MCL) patients aged <60 years who did not receive stem cell transplantation (SCT) despite medical eligibility. Complete response (CR)/unconfirmed CR (CRu) rates were 67 vs. 39% (odds ratio 3.69 [95% CI(confidence interval): 1.31, 10...
January 17, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29337223/sequential-conditioning-with-thiotepa-in-t-cell-replete-hematopoietic-stem-cell-transplantation-for-the-treatment-of-refractory-hematological-malignancies-comparison-with-matched-related-haplo-mismatched-and-unrelated-donors
#4
Rémy Duléry, Anne-Lise Ménard, Sylvain Chantepie, Jean El Cheikh, Sylvie François, Jérémy Delage, Federica Giannotti, Annalisa Ruggeri, Eolia Brissot, Giorgia Battipaglia, Florent Malard, Ramdane Belhocine, Simona Sestili, Anne Vekhoff, François Delhommeau, Oumédaly Reman, Ollivier Legrand, Myriam Labopin, Marie-Thérèse Rubio, Mohamad Mohty
The results of conventional allogeneic stem cell transplantation (SCT) in refractory hematological malignancies are poor. Sequential strategies have shown promising results in refractory acute myeloid leukemia (AML), but have not been validated in a haploidentical (Haplo) setting. We developed a new sequential approach combining chemotherapy with broad anti-tumor activity (thiotepa 10 mg/kg, etoposide 400 mg/m2, cyclophosphamide 1600 mg/m2 from Day-15 to -10), followed after 3 days of rest by reduced-intensity conditioning regimen (fludarabine 150 mg/m2, intravenous busulfan 6...
January 11, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29337025/hepatosplenic-t-cell-lymphoma-a-review-of-clinicopathologic-features-pathogenesis-and-prognostic-factors
#5
Mariko Yabe, Roberto N Miranda, L Jeffrey Medeiros
Hepatosplenic T-cell lymphoma (HSTCL) is a rare and clinically aggressive type of T-cell lymphoma that arises most often in adolescents and young adults. Patients with HSTCL commonly present with B-symptoms and cytopenias which may suggest a diagnosis of acute leukemia initially. Patients present with extranodal disease involving the spleen, liver and bone marrow; lymphadenopathy is usually absent. The lymphoma cells can show a spectrum of cell sizes and are of T-cell lineage, often negative for CD4 and CD8 and positive for T-cell receptor γδ or, less often, αβ...
January 11, 2018: Human Pathology
https://www.readbyqxmd.com/read/29335632/long-term-outcome-analysis-of-reduced-intensity-allogeneic-stem-cell-transplantation-in-patients-with-mantle-cell-lymphoma-a-retrospective-study-from-the-ebmt-lymphoma-working-party
#6
Stephen P Robinson, Ariane Boumendil, Herve Finel, Karl S Peggs, Patrice Chevallier, Jorge Sierra, Jürgen Finke, Xavier Poiré, Natacha Maillard, Noël Milpied, Ibrahim Yakoub-Agha, Mickey Koh, Nicolaus Kröger, Arnon Nagler, Yener Koc, Sascha Dietrich, Silvia Montoto, Peter Dreger
Reduced-intensity allogeneic stem cell transplantation (RIST) is usually reserved for patients with mantle cell lymphoma who relapse after an autoSCT. However, the long-term efficacy of RIST and its curative potential have not been clearly demonstrated. We studied the long-term outcome of patients receiving a RIST for MCL as reported to the EBMT. A total of 324 patients, median age 57 years (range 31-70), underwent a RIST between 2000 and 2008; 43% of the patients had received >3 lines of prior therapy, including an autoSCT in 46%...
January 15, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29335071/adequate-concentration-of-b-cell-leukemia-lymphoma-3-bcl3-is-required-for-pluripotency-and-self-renewal-of-mouse-embryonic-stem-cells-via-downregulation-of-nanog-transcription
#7
Songhwa Kang, Jisoo Yun, Da Yeon Kim, Seok Yun Jung, Yeon Ju Kim, Ji Hye Park, Seung Taek Ji, Woong Bi Jang, Joungsung Ha, Jae Ho Kim, Sang Hong Baek, Sang-Mo Kwon
B cell leukemia/lymphoma 3 (Bcl3) plays a pivotal role in immune homeostasis, cellular proliferation, and cell survival, as a co-activator or co-repressor of transcription of the NF-κB family. Recently, it was reported that Bcl3 positively regulates pluripotency genes, including Oct4, in mouse embryonic stem cells (mESCs). However, the role of Bcl3 in the maintenance of pluripotency and self-renewal activity is not fully established. Here, we report the dynamic regulation of the proliferation, pluripotency, and self-renewal of mESCs by Bcl3 via an influence on Nanog transcriptional activity...
January 16, 2018: BMB Reports
https://www.readbyqxmd.com/read/29334819/management-of-hodgkin-lymphoma-in-the-era-of-brentuximab-vedotin-real-world-data-from-five-european-countries
#8
Graham P Collins, Antonio Rueda, Gilles Salles, Bastian von Tresckow, Francesco Zaja
We examined real-world data on management of relapsed/refractory Hodgkin lymphoma (R/R HL) in five European countries and the consistency of these data with guideline recommendations. Retrospective clinical and epidemiologic data for 509 patients with R/R HL treated between January 2014 and March 2015 were collected at centers in France, Germany, Italy, Spain, and the United Kingdom. Mean age was 46.3 years; 73.3% were receiving second-line therapy for a first relapse during the reporting period. Most patients received ABVD as front-line chemotherapy, except in Germany where escalated BEACOPP was used more often...
January 16, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29333021/efficacy-and-safety-of-ibrutinib-in-indian-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cases-from-a-named-patient-program
#9
Mohan B Agarwal, Dinesh Bhurani, Chirag Shah, Nitin Sood, Manish Singhal, Anil Kamat, Subash Chezhian, Suryaprakash Mishra, Dinesh Nagrale
Context: This named patient program evaluated the safety and efficacy of ibrutinib, a selective inhibitor of Bruton's tyrosine kinase in Indian patients with relapsed/refractory chronic lymphocytic leukemia (CLL, with/without chromosome 17 deletion [del17p]) and mantle cell lymphoma (MCL). Subjects and Methods: The eight enrolled patients (relapsed/refractory CLL: n = 6 [4/6 patients with del17p] and relapsed/refractory MCL: n = 2) had median age of 55 years (range, 52-60) and had received a median of 3 (CLL patients) and 4 (MCL patients) prior therapies...
October 2017: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/29330395/predicting-failure-of-hematopoietic-stem-cell-mobilization-before-it-starts-the-predicted-poor-mobilizer-ppm-score
#10
Jacopo Olivieri, Immacolata Attolico, Roberta Nuccorini, Sara Pasquina Pascale, Martina Chiarucci, Monica Poiani, Paolo Corradini, Lucia Farina, Gianluca Gaidano, Luca Nassi, Simona Sica, Nicola Piccirillo, Pietro Enrico Pioltelli, Massimo Martino, Tiziana Moscato, Massimo Pini, Francesco Zallio, Fabio Ciceri, Sarah Marktel, Andrea Mengarelli, Pellegrino Musto, Saveria Capria, Francesco Merli, Katia Codeluppi, Giuseppe Mele, Francesco Lanza, Giorgina Specchia, Domenico Pastore, Giuseppe Milone, Francesco Saraceni, Elvira Di Nardo, Paolo Perseghin, Attilio Olivieri
Predicting mobilization failure before it starts may enable patient-tailored strategies. Although consensus criteria for predicted PM (pPM) are available, their predictive performance has never been measured on real data. We retrospectively collected and analyzed 1318 mobilization procedures performed for MM and lymphoma patients in the plerixafor era. In our sample, 180/1318 (13.7%) were PM. The score resulting from published pPM criteria had sufficient performance for predicting PM, as measured by AUC (0...
January 12, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29328385/tormentic-acid-inhibits-il-1%C3%AE-induced-chondrocyte-apoptosis-by-activating-the-pi3k-akt-signaling-pathway
#11
Yang Yang, Yawei Wang, Meng Zhao, Haobo Jia, Bing Li, Dan Xing
Interleukin-1β (IL-1β) accelerates degradation of the cartilage matrix and induces apoptosis of chondrocytes. Tormentic acid (TA) is a triterpene isolated from the stem bark of the Vochysia divergens plant, which has been demonstrated to exert in vitro inhibitory activity against hepatocyte apoptosis. However, the effects of TA on IL‑1β‑induced apoptosis of human chondrocytes remain unclear. Therefore, the present study investigated the in vitro effects of TA on human osteoarthritic chondrocyte apoptosis cultivated in the presence of IL‑1β...
January 12, 2018: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29325898/treatment-of-mantle-cell-lymphoma-in-older-adults
#12
REVIEW
Daniel F Pease, Vicki A Morrison
Mantle cell lymphoma (MCL) predominantly affects older adults, with a median age at diagnosis of 70years. A frequently aggressive yet incurable lymphoma, the goal of therapy for MCL is to turn a potentially life-threatening illness into a chronic disease with prolonged periods of remission. Large randomized trial data supports the standard treatment in younger patients of cytarabine-based induction followed by autologous stem cell transplant. Most patients will not be eligible for this intensive approach based on older age, comorbidities, and functional status, making the geriatric assessment an essential step in choosing the appropriate strategy...
January 8, 2018: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/29324208/solid-organ-transplantation-in-patients-with-a-history-of-lymphoma
#13
Philip J Bierman
There is an increasing number of long-term survivors of Hodgkin and non-Hodgkin lymphoma. These people may have a need for subsequent solid organ transplantation, often as a result of late effects of their lymphoma treatment. There is abundant literature demonstrating that patients with a history of lymphoma are appropriate candidates for solid organ transplantation. Long-term survival without relapse and with a functioning graft is possible. Patients with a history of post-transplantation lymphoproliferative disorders and patients who have received a prior hematopoietic stem-cell transplantation may also be candidates...
January 2018: Journal of Oncology Practice
https://www.readbyqxmd.com/read/29323537/investigational-therapies-targeting-cd37-for-the-treatment-of-b-cell-lymphoid-malignancies
#14
Magdalena Witkowska, Piotr Smolewski, Tadeusz Robak
While chemotherapy still remains a cornerstone of oncologic therapy, immunotherapy with monoclonal antibodies has steadily improved the treatment strategy for several hematologic malignancies. New treatment options need to be developed for relapsed and refractory non-Hodgkin lymphoma (NHL) patients. Currently, novel agents targeting specific molecules on the surface of lymphoma cells, such as anti-CD37 antibodies, are under considerable investigation. Here we report on anti-CD37 targeting for the treatment of patients with B-cell NHL...
January 11, 2018: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/29321654/motivating-cord-blood-donation-with-information-and-behavioral-nudges
#15
Daniela Grieco, Nicola Lacetera, Mario Macis, Daniela Di Martino
Umbilical cord blood is a source of hematopoietic stem cells essential to treat life-threatening diseases, such as leukemia and lymphoma. However, only a very small percentage of parents donate upon delivery. The decision to donate the cord blood occurs at a very specific time and when parents likely experience emotional, informational, and decisional overloads; these features of cord blood donation make it different from other pro-social activities. In collaboration with an OB-GYN clinic in Milan, Italy, we conducted the first randomized controlled trial that applies tools from behavioral science to foster cord blood donation, and quantified the gains that informational and behavioral "nudges" can achieve...
January 10, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29314206/follicular-lymphoma-2018-update-on-diagnosis-and-management
#16
Arnold Freedman
DISEASE OVERVIEW: Follicular lymphoma is generally an indolent B cell lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma (FL) is characterized by diffuse lymphadenopathy, bone marrow involvement, splenomegaly and less commonly other extranodal sites of involvement. In general, cytopenias can occur but constitutional symptoms of fever, nightsweats, and weight loss are uncommon. DIAGNOSIS: Diagnosis is based on histology of preferably a biopsy of a lymph node...
February 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29304536/defibrotide-stimulates-angiogenesis-and-protects-endothelial-cells-from-calcineurin-inhibitor-induced-apoptosis-via-upregulation-of-akt-bcl-xl
#17
Xiangmin Wang, Bin Pan, Yuko Hashimoto, Hiroshi Ohkawara, Kailin Xu, Lingyu Zeng, Takayuki Ikezoe
Sinusoidal obstruction syndrome is a life-threatening complication that can occur after haematopoietic stem cell transplantation. Defibrotide (DF) has been approved for the treatment of individuals with severe sinusoidal obstruction syndrome following haematopoietic stem cell transplantation in the European Union and the United States. However, the precise mechanisms by which DF protects endothelial cells remain to be elucidated. In this study, we found that DF stimulated angiogenesis in vitro and in vivo as assessed by vascular tube formation, scratch-wound repair and Matrigel plug assays...
January 2018: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/29303041/changes-in-the-microbiological-epidemiology-of-febrile-neutropenia-in-autologous-stem-cell-transplant-recipients
#18
Rosa Rönkkö, Auni Juutilainen, Irma Koivula, Matti Vänskä, Tapio Nousiainen, Esa Jantunen, Sari Hämäläinen
BACKGROUND: The aim of the study was to explore the incidence, microbiological etiology and outcome of febrile neutropenia among adult hematological patients following autologous stem cell transplantation (ASCT). METHODS: The study population consisted of patients who received ASCT between 1 December 2006 and 30 November 2012. The epidemiology was compared to a retrospective series covering eleven previous years at the same institution. Non-Hodgkin lymphoma (NHL) patients, who had been identified as a risk group in the retrospective study, received ciprofloxacin prophylaxis from January 2008...
January 5, 2018: Infectious Diseases
https://www.readbyqxmd.com/read/29297171/treatment-of-hiv-associated-lymphomas-the-latest-approaches-for-optimizing-outcomes
#19
Natasha B Hunter, Samantha Vogt, Richard F Ambinder
Treatment outcomes for patients with HIV-related lymphoma have improved since the advent of combination antiretroviral therapy. Standard regimens, including intensive regimens, are being used with encouraging results in patients with diffuse large B-cell lymphoma, Burkitt lymphoma, Hodgkin lymphoma, and primary central nervous system lymphoma. Approaches to salvage therapy also parallel those used in patients without HIV infection, including autologous and allogeneic hematopoietic stem cell transplant. Drug interactions with particular antiretrovirals warrant close attention...
December 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29296894/mature-lymphoid-malignancies-origin-stem-cells-and-chronicity
#20
REVIEW
Simon Husby, Kirsten Grønbæk
The chronic behavior of mature lymphoid malignancies, with relapses occurring years apart in many patients, has until recently been unexplained. Patterns of relapse also differ vastly between disease entities, with some being highly curable by chemotherapy whereas others are destined to reemerge after treatment. Lately, the use of next-generation sequencing techniques has revealed essential information on the clonal evolution of lymphoid malignancies. Also, experimental xenograft transplantation point to the possible existence of an ancestral (stem) cell...
November 28, 2017: Blood Advances
keyword
keyword
103609
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"